About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and ...

Blood cancer is the low-hanging fruit for Chimeric Therapeutics, but the company is targeting more from its next-gen Car-T ...

Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed ...

The Filipino-born artist takes a journey through primordial mud, chimeric worlds, and suppressed psychic demons to honor trans people as channels of divinity.

These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the ...

1 Obe-cel is a chimeric antigen receptor (CAR) T-cell therapy that is the first approved by the FDA without a requirement for ...

In healthy brains, immune cells called microglia patrol for damage, clearing away debris and harmful proteins. But in the ...

Carisma Therapeutics (CARM) announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte, or CAR-M, therapy for hepatocellular carcinoma, or HCC, ...

The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...

The origins of autoimmune diseases like it are often mysterious, and an immune system that sees the body it inhabits as an ...